Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],46.0,5067,DB00098,Antithymocyte globulin
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],69.0,5068,DB00098,Antithymocyte globulin
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],25.2,5069,DB00098,Antithymocyte globulin
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],45.4,5070,DB00098,Antithymocyte globulin
,26064352,total response rates,"In an average follow-up period of 12 months, the total response rates (66.7%) in two groups were same.",Pharmacokinetics and pharmacodynamics of two antithymocyte globulins in treatment of pediatric aplastic anemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064352/),%,66.7,16013,DB00098,Antithymocyte globulin
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,21,30243,DB00098,Antithymocyte globulin
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,66,30244,DB00098,Antithymocyte globulin
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,18,30245,DB00098,Antithymocyte globulin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,74,30246,DB00098,Antithymocyte globulin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30247,DB00098,Antithymocyte globulin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30248,DB00098,Antithymocyte globulin
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30249,DB00098,Antithymocyte globulin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,88,30250,DB00098,Antithymocyte globulin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30251,DB00098,Antithymocyte globulin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30252,DB00098,Antithymocyte globulin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30253,DB00098,Antithymocyte globulin
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,71,30254,DB00098,Antithymocyte globulin
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.60,30255,DB00098,Antithymocyte globulin
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.57,30256,DB00098,Antithymocyte globulin
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.77,30257,DB00098,Antithymocyte globulin
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.86,30258,DB00098,Antithymocyte globulin
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.92,30259,DB00098,Antithymocyte globulin
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.96,30260,DB00098,Antithymocyte globulin
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4866.51,30261,DB00098,Antithymocyte globulin
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4980,30262,DB00098,Antithymocyte globulin
,16578989,area under the plasma concentration-time curve (AUC),"The mean area under the plasma concentration-time curve (AUC) and the half-life of the first dose of intravenously administered busulfan were 6,253 microM x minute (range, 5,036-7,482 microM x minute) and 3.37 hours (range, 2.54-4.00 hours), respectively.",Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16578989/),min·μM,"6,253",38991,DB00098,Antithymocyte globulin
,16578989,half-life,"The mean area under the plasma concentration-time curve (AUC) and the half-life of the first dose of intravenously administered busulfan were 6,253 microM x minute (range, 5,036-7,482 microM x minute) and 3.37 hours (range, 2.54-4.00 hours), respectively.",Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16578989/),h,3.37,38992,DB00098,Antithymocyte globulin
,11680569,overall treatment success rate,"Antibodies binding to human lymphocytes (active Thymoglobulin), were determined by flow cytometry; no correlation was seen between treatment efficacy and either active or total Thymoglobulin concentrations; the overall treatment success rate was 86%.",Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11680569/),%,86,42915,DB00098,Antithymocyte globulin
,17924828,AUC(0-12),"Differences in the MPA pharmacokinetic profiles confirmed large interpatient variability of MPA exposure, with AUC(0-12) values ranging from 7.9 to 50.1 mg*h/ml.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [ml],7.9 to 50.1,47677,DB00098,Antithymocyte globulin
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],61.5,47678,DB00098,Antithymocyte globulin
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],45.4,47679,DB00098,Antithymocyte globulin
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],40.8,47680,DB00098,Antithymocyte globulin
below,16151422,first dose trough level (C(min)-1),"Six patients rejected the graft, two in the busulfan 600 mg group and four in busulfan 16 mg group (P = 0.677 CI -0.17, 0.07), but in five patients (pharmacokinetic data not available in one patient) who rejected the graft busulfan first dose trough level (C(min)-1) was below 150 ng/ml while it was above this level in the 66 of 68 patients with successful engraftment (P < or = 0.001).",Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16151422/),[ng] / [ml],150,50371,DB00098,Antithymocyte globulin
,10480415,elimination t1/2,"HuM291 exhibited a long elimination t1/2 (81.5 hr) and, after three 10-mg doses, sustained serum concentrations > 1000 ng/ml were maintained for 1 week.","A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10480415/),h,81.5,66020,DB00098,Antithymocyte globulin
,17490543,elimination half-life (t(1/2) beta),"The results showed that the washout phase of ATG elimination was analyzed over 0 - 120 days, results were well-fitted by a single exponential decay giving a mean elimination half-life (t(1/2) beta) of 29.67 +/- 2.60 days.",[Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17490543/),d,29.67,66186,DB00098,Antithymocyte globulin
,17490543,apparent volume of distribution of ATG (V),A mean value for the apparent volume of distribution of ATG (V) obtained by analysis of data was 0.12 +/- 0.02 L/kg body weight.,[Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17490543/),[l] / [kg],0.12,66187,DB00098,Antithymocyte globulin
,17490543,peak concentration,"The serum concentration of ATG increased up to 44.8% at 5 day before transplantation, peak concentration of ATG was 136.0 +/- 10.3 mg/L, its concentration slowly descend at 0 day, fall up to 7.1 +/- 0.06 microg/ml at 90 day after dosing; t(max) 4.8 +/- 0.7 days; According to AIC (Akaike's information criterion), two compartment model of ATG was estimated.",[Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17490543/),[mg] / [l],136.0,66188,DB00098,Antithymocyte globulin
,17490543,t(max),"The serum concentration of ATG increased up to 44.8% at 5 day before transplantation, peak concentration of ATG was 136.0 +/- 10.3 mg/L, its concentration slowly descend at 0 day, fall up to 7.1 +/- 0.06 microg/ml at 90 day after dosing; t(max) 4.8 +/- 0.7 days; According to AIC (Akaike's information criterion), two compartment model of ATG was estimated.",[Pharmacokinetics of antithymocyte globulin in recipients under-going HLA partially matched hematopoietic stem cell transplantation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17490543/),d,4.8,66189,DB00098,Antithymocyte globulin
,8616954,elimination half-life (t0.5e),"The washout phase of ATG elimination was analysed over 0-300 days; results were well-fitted by a single exponential decay (r2 > 0.95) giving a mean elimination half-life (t0.5e) of 29.8 days (range 14.3-45.0, n = 9).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),d,29.8,113057,DB00098,Antithymocyte globulin
,8616954,apparent volume of distribution of ATG (Vd),"Data for the first 4 days of treatment were analysed with linear regression to obtain a mean value for the apparent volume of distribution of ATG (Vd) of 0.12 l/kg body weight (range 0.07 to 0.17, n = 5).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),[l] / [body·kg·weight],0.12,113058,DB00098,Antithymocyte globulin
,26025482,area under the curve (AUC),"Bu regimen doses, adjusted to target an area under the curve (AUC) of 4000 μMol*minute per day in a first cohort (n = 12) and 5000 μMol*minute in a second cohort (n = 21).",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),[min·μMol] / [d],4000,116023,DB00098,Antithymocyte globulin
,26025482,area under the curve (AUC),"Bu regimen doses, adjusted to target an area under the curve (AUC) of 4000 μMol*minute per day in a first cohort (n = 12) and 5000 μMol*minute in a second cohort (n = 21).",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),min·μMol,5000,116024,DB00098,Antithymocyte globulin
,26025482,clearance,"The mean Bu clearance in our infant patients was found to be 3.67 ± 1.03 mL/minute/kg, and the test dose clearance was highly predictive of the regimen dose clearance.",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),[ml] / [kg·min],3.67,116025,DB00098,Antithymocyte globulin
,26025482,AUC,The mean AUC achieved after the first single daily regimen dose was 3951 ± 1239 in the AUC 4000 cohort and 4884 ± 766 for the AUC 5000 cohort.,Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),,3951,116026,DB00098,Antithymocyte globulin
,26025482,AUC,The mean AUC achieved after the first single daily regimen dose was 3951 ± 1239 in the AUC 4000 cohort and 4884 ± 766 for the AUC 5000 cohort.,Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),,4884,116027,DB00098,Antithymocyte globulin
,26025482,Overall survival,"Overall survival of patients at 6 years after transplantation was 59.5% for the AUC 4000 cohort and 85.4% for the AUC 5000 cohort, with primary graft failure in the first cohort being a major contributor to morbidity.",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),%,59,116028,DB00098,Antithymocyte globulin
,26025482,Overall survival,"Overall survival of patients at 6 years after transplantation was 59.5% for the AUC 4000 cohort and 85.4% for the AUC 5000 cohort, with primary graft failure in the first cohort being a major contributor to morbidity.",Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),%,85,116029,DB00098,Antithymocyte globulin
,26025482,AUC,The difference in clinical outcomes between the 2 cohorts supports the conclusion that targeting a higher Bu AUC of 5000 μMol*minute per day for 2 days improves donor engraftment in infants with nonmalignant conditions undergoing RIC HPCT without increasing toxicity.,Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26025482/),[min·μMol] / [d],5000,116030,DB00098,Antithymocyte globulin
,30831208,absolute lymphocyte count,"On the first day of ATG administration (day -3), the median absolute lymphocyte count was .0 K/µL.",Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831208/),[k] / [μl],.0,133292,DB00098,Antithymocyte globulin
,30831208,disease-free survival (,"At 3 years post-HCT, for patients who received a total dose of ATG >450 mg or ≤450 mg, nonrelapse mortality (NRM) rates were 35% and 18%, respectively (P = .029), disease-free survival (DFS) rates were 37% and 61%, respectively (P = .003), and OS rates were 40% and 67%, respectively (P = .001).",Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831208/),%,37,133293,DB00098,Antithymocyte globulin
,30831208,disease-free survival (,"At 3 years post-HCT, for patients who received a total dose of ATG >450 mg or ≤450 mg, nonrelapse mortality (NRM) rates were 35% and 18%, respectively (P = .029), disease-free survival (DFS) rates were 37% and 61%, respectively (P = .003), and OS rates were 40% and 67%, respectively (P = .001).",Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30831208/),%,61,133294,DB00098,Antithymocyte globulin
,16545731,area under the concentration-time curve (AUC),"A test dose of IV Bu (0.8 mg/kg), anticipated to target an area under the concentration-time curve (AUC) of 800 to 1200 micromol.",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),μM,800 to 1200,135851,DB00098,Antithymocyte globulin
,16545731,AUC,"min, was followed later by 2 daily doses adjusted according to the pharmacokinetics (PK) to target an AUC of 3200 to 4800 micromol.min.",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),min·μM,3200 to 4800,135852,DB00098,Antithymocyte globulin
,16545731,AUC,"The median test dose AUC was 953 micromol.min (range, 439-1315 micromol.min).",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),min·μM,953,135853,DB00098,Antithymocyte globulin
,16545731,AUC,"The median AUC of single daily doses was 3798 micromol.min (range, 1511-7254 micromol.min).",Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16545731/),min·μM,3798,135854,DB00098,Antithymocyte globulin
,12869960,peak levels,"Recipients of 6 mg/kg r-ATG had peak levels of total and active r-ATG of 64+/-20 microg/mL and 9.2+/-5.8 microg/mL, respectively, with clearance of active r-ATG (t(1/2)6 days) to sub-therapeutic levels (<1 microg/mL) by a median of 15 days posttransplantation (range, 8-38 days).",Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869960/),[μg] / [ml],64,144491,DB00098,Antithymocyte globulin
,12869960,peak levels,"Recipients of 6 mg/kg r-ATG had peak levels of total and active r-ATG of 64+/-20 microg/mL and 9.2+/-5.8 microg/mL, respectively, with clearance of active r-ATG (t(1/2)6 days) to sub-therapeutic levels (<1 microg/mL) by a median of 15 days posttransplantation (range, 8-38 days).",Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869960/),[μg] / [ml],9.2,144492,DB00098,Antithymocyte globulin
,15561259,AUC,"Comparing the AUC/mg dose, PK-1 was much lower than PK-2 (25.2 +/- 11.4 ng x h/mg x mL vs 45.4 +/- 12.9 ng x h/mg x mL; P = .0005 using paired t test).",A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561259/),[h·ng] / [mg·ml],25.2,147140,DB00098,Antithymocyte globulin
,15561259,AUC,"Comparing the AUC/mg dose, PK-1 was much lower than PK-2 (25.2 +/- 11.4 ng x h/mg x mL vs 45.4 +/- 12.9 ng x h/mg x mL; P = .0005 using paired t test).",A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561259/),[h·ng] / [mg·ml],45.4,147141,DB00098,Antithymocyte globulin
,20305698,AUC,Median AUC was 963 μmol min/L (range 780-1305 μmol min/L).,Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305698/),[min·μM] / [l],963,171282,DB00098,Antithymocyte globulin
,20305698,AUC,Lower AUC was seen with partial donor chimerism (862 ± 73 μmol min/L) versus full donor chimerism (AUC 1018 ± 122 μmol min/L) (P = 0.022).,Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305698/),[min·μM] / [l],862,171283,DB00098,Antithymocyte globulin
,20305698,AUC,Lower AUC was seen with partial donor chimerism (862 ± 73 μmol min/L) versus full donor chimerism (AUC 1018 ± 122 μmol min/L) (P = 0.022).,Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20305698/),[min·μM] / [l],1018,171284,DB00098,Antithymocyte globulin
,34022093,Overall survival,"Busulfan pharmacokinetics were measured to target 4000 μmol*min/day in the first 30 patients; this was increased to 5000 μmol*min/day in the subsequent 10 in efforts to further decrease relapse risk RESULTS: Overall survival at two- and five-years post-HCT was 67% and 51%, respectively.","Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),%,67,172014,DB00098,Antithymocyte globulin
,34022093,Overall survival,"Busulfan pharmacokinetics were measured to target 4000 μmol*min/day in the first 30 patients; this was increased to 5000 μmol*min/day in the subsequent 10 in efforts to further decrease relapse risk RESULTS: Overall survival at two- and five-years post-HCT was 67% and 51%, respectively.","Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),%,51,172015,DB00098,Antithymocyte globulin
>,34022093,AUC,Trends toward improved survival were seen in patients transplanted for myeloid disease using bone marrow as stem cell source who achieved a busulfan AUC > 4000 μmol*min/day with two-year relapse-free survival approaching 80% CONCLUSIONS:,"Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34022093/),[min·μM] / [d],4000,172016,DB00098,Antithymocyte globulin
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],44.40,209031,DB00098,Antithymocyte globulin
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],158.01,209032,DB00098,Antithymocyte globulin
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],92.23,209033,DB00098,Antithymocyte globulin
,7570988,terminal half-life,The chRFT5 had a long terminal half-life with a mean of 13.1 days.,Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7570988/),d,13.1,218691,DB00098,Antithymocyte globulin
,31212080,area under the curve (AUC),"On this phase II multicenter study, 63 patients (40 unrelated donors and 23 matched related donors) received a uniform conditioning regimen consisting of fludarabine i.v. (days -7 to -3), BU targeted to a daily area under the curve (AUC) of 4000 μM/min (days -6 to -3) after the administration of a 25-mg/m2 i.v. test dose on 1 day between days -14 to -9, and antithymocyte globulin (days -6, -5, and -4 (2 doses for matched related donors and 3 for matched unrelated donors only).",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),[μM] / [min],4000,218958,DB00098,Antithymocyte globulin
,31212080,overall survival,"The probability of overall survival at 2 and 5 years was 45.7% (95% CI, 34.9%-59.9%) and 31.2% (95% CI, 21.3% to 45.8%), respectively, for the entire group with a median overall survival of 19.2 months (95% CI, 8.7 to 37.5).",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),month,19.2,218959,DB00098,Antithymocyte globulin
,31212080,AUC,"In summary, we demonstrated the feasibility of a novel reduced-intensity conditioning regimen with test dose BU targeted to an AUC of 4000 μM/min.",A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212080/),[μM] / [min],4000,218960,DB00098,Antithymocyte globulin
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],29,239826,DB00098,Antithymocyte globulin
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],18,239827,DB00098,Antithymocyte globulin
,11264639,clearance,Both were significantly lower compared with a clearance of 37+/-15 mL/h from a previous study of basiliximab with dual therapy (p<0.001).,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],37,239828,DB00098,Antithymocyte globulin
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239829,DB00098,Antithymocyte globulin
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239830,DB00098,Antithymocyte globulin
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239831,DB00098,Antithymocyte globulin
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239832,DB00098,Antithymocyte globulin
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239833,DB00098,Antithymocyte globulin
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239834,DB00098,Antithymocyte globulin
,11148182,trough concentrations (C(min)),"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],1.63,241348,DB00098,Antithymocyte globulin
,11148182,trough concentrations (C(min)),"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.29,241349,DB00098,Antithymocyte globulin
,11148182,areas under the curve (AUCs) for,"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,39.80,241350,DB00098,Antithymocyte globulin
,11148182,areas under the curve (AUCs) for,"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,62.10,241351,DB00098,Antithymocyte globulin
,11148182,C(min),"In this group, the MPA-C(min) and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 +/- 0.45 mg/L and 25.00 +/- 6.20 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),,1.,241352,DB00098,Antithymocyte globulin
,11148182,AUC,"In this group, the MPA-C(min) and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 +/- 0.45 mg/L and 25.00 +/- 6.20 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,25.00,241353,DB00098,Antithymocyte globulin
,11148182,C(min),C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.22,241354,DB00098,Antithymocyte globulin
,11148182,C(min),C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.17,241355,DB00098,Antithymocyte globulin
,11148182,AUC,C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,66.82,241356,DB00098,Antithymocyte globulin
,11148182,AUC,C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,55.70,241357,DB00098,Antithymocyte globulin
,11148182,C(30),h/L (P = 0.11)]; and C(30) was significantly higher in group 2 than in group 1 (C(30) = 32.99 +/- 12.59 vs 7.45 +/- 5.40 mg/L; P <0.0001).,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],32.99,241358,DB00098,Antithymocyte globulin
,11148182,C(30),h/L (P = 0.11)]; and C(30) was significantly higher in group 2 than in group 1 (C(30) = 32.99 +/- 12.59 vs 7.45 +/- 5.40 mg/L; P <0.0001).,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],7.45,241359,DB00098,Antithymocyte globulin
,23507258,Maximum concentrations,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),μ,6.2,258730,DB00098,Antithymocyte globulin
,23507258,terminal half-lives,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),μ,6.2,258731,DB00098,Antithymocyte globulin
,23507258,dose-normalized AUC,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),[dayg] / [ml],374,258732,DB00098,Antithymocyte globulin
,23507258,dose-normalized AUC,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),[dayg] / [ml],508,258733,DB00098,Antithymocyte globulin
<,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,1,258734,DB00098,Antithymocyte globulin
,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,18.75,258735,DB00098,Antithymocyte globulin
,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,20,258736,DB00098,Antithymocyte globulin
less,9408695,Cmin,Doses of oral GAN were increased if Cmin levels were less than 0.5-1.0 microgram/ml.,Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408695/),[μg] / [ml],0.5-1.0,267685,DB00098,Antithymocyte globulin
,6983972,half-life,"Il 2 was cleared equally rapidly, with a half-life of 3 min, from the blood of both groups of mice.",Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6983972/),min,3,271009,DB00098,Antithymocyte globulin
